Serial Cerebrospinal Fluid Neurofilament Heavy Chain Levels In Severe Guillain-Barré Syndrome

Muscle and Nerve

Volumn 48, Issue 1, 2013, Pages 132-134

  Dujmovic, Irena ^a   Lunn, Michael P ^b   Reilly, Mary M ^c   Petzold, Axel ^c,d  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Axonal degeneration; Cerebrospinal fluid; Guillain Barr syndrome; Neurofilaments; Prognosis

Indexed keywords

IMMUNOGLOBULIN G; NEUROFILAMENT PROTEIN; SMI35 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREFLEXIA; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL TRIAL; DISEASE MARKER; DISEASE SEVERITY; GUILLAIN BARRE SYNDROME; HUMAN; MALE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPHYSIOLOGY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; NEUROFILAMENT PROTEINS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84879556358     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23752     Document Type: Article

References (20)

1. Guillain G, Barrr JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracta res cliniques et graphiques des reflexes tendineux. Bull Soc Med Hosp Paris 1916;40:1462-1470.
2. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain 1986;109:1115-1126.
3. Brettschneider J, Petzold A, Sussmuth S, Tumani H. Cerebrospinal fluid biomarkers in Guillain-Barre syndrome - where do we stand? J Neurol 2009;256:3-12.
4. Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome. Neurology 2006;67:1071-1073.
5. Petzold A, Brettschneider J, Jin K, Keir G, Murray NMF, Hirsch NP, et al. Cerebrospinal fluid protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barre syndrome. Muscle Nerve 2009;40:42-49.
6. Dujmovic I. cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult Scler Int 2011;2011:767083.
7. Medical Research Council. Aids to the investigation of the peripheral nervous system. London: Her Majesty's Stationary Office; 1943. p 1-2.
8. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54:943-949.
9. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
10. Kleyweg R, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991;14:1103-1109.
11. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
12. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998;44:780-788.
13. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435-451.
14. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190.
15. Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007;319:34-40.
16. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, et al. Neurofilament ELISA validation. J Immunol Methods 2010;352:23-31.
17. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol 1996;39:17-28.
18. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999;100:74-97.
19. Van Koningsveld R, Steyerberg EW, Hughes R, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-594.
20. Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJP, et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 2010;67:781-787.